The Effects of CYP2C19 Genotype on Proxies of SSRI Antidepressant Response in the UK Biobank
The Effects of CYP2C19 Genotype on Proxies of SSRI Antidepressant Response in the UK Biobank
About this item
Full title
Author / Creator
Publisher
Switzerland: MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: MDPI AG
Subjects
More information
Scope and Contents
Contents
Selective serotonin reuptake inhibitors (SSRIs) are the most commonly used psychopharmaceutical treatment for major depressive disorder (MDD), but individual responses to SSRIs vary greatly. CYP2C19 is a key enzyme involved in the metabolism of several drugs, including SSRIs. Variations in the CYP2C19 gene are associated with differential metabolic...
Alternative Titles
Full title
The Effects of CYP2C19 Genotype on Proxies of SSRI Antidepressant Response in the UK Biobank
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_2f15a871d7a8490b93802d961572eeae
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_2f15a871d7a8490b93802d961572eeae
Other Identifiers
ISSN
1424-8247
E-ISSN
1424-8247
DOI
10.3390/ph16091277
